论文部分内容阅读
目的:评价紫杉醇联合卡铂治疗复发性上皮性卵巢癌的近期疗效及不良反应。方法:复发性上皮性卵巢癌48例,采用紫杉醇联合卡铂治疗(TP)26例,随机对采用顺铂+阿霉素+环磷酰胺(CAP)治疗22例作为对照组。紫杉醇135 mg/m2,静脉滴注;卡铂300~400 mg/m2,静脉滴注,3~4周重复。顺铂70~80 mg/m2,分3天静脉滴注;阿霉素50 mg/m2,分2天静脉推注;环磷酰胺500 mg/m2,静脉推注。结果:48例均可评价疗效,TP组治疗有效率69.2%,CAP组治疗有效率40.9%,两组间疗效比较有统计学意义(P<0.05)。TP组主要不良反应为骨髓抑制、胃肠道反应、肌肉关节疼痛和周围神经毒性,Ⅳ度不良反应主要为白细胞减少和胃肠道反应。结论:紫杉醇联合卡铂方案可作为复发性上皮性卵巢癌的首选药物,治疗有效率优于传统的顺铂+阿霉素+环磷酰胺方案,值得推广应用。
Objective: To evaluate the short-term efficacy and side effects of paclitaxel combined with carboplatin in the treatment of recurrent epithelial ovarian cancer. Methods: Forty-eight patients with recurrent epithelial ovarian cancer were treated with paclitaxel combined with carboplatin (TP). Twenty-two patients were randomly divided into control group and cisplatin + doxorubicin plus cyclophosphamide (CAP). Paclitaxel 135 mg / m2, intravenous infusion; carboplatin 300 ~ 400 mg / m2, intravenous infusion, 3 to 4 weeks repeated. Cisplatin 70 ~ 80 mg / m2, intravenous drip three days; doxorubicin 50 mg / m2, intravenous injection 2 days; cyclophosphamide 500 mg / m2, intravenous injection. Results: The curative effect was evaluated in 48 cases. The effective rate of TP group was 69.2% and that of CAP group was 40.9%. The curative effect between the two groups was statistically significant (P <0.05). The main adverse reactions of TP group were myelosuppression, gastrointestinal reaction, muscle and joint pain and peripheral neurotoxicity. The main adverse reactions of grade Ⅳ were leukopenia and gastrointestinal reaction. Conclusion: Paclitaxel combined with carboplatin can be used as the drug of choice for recurrent epithelial ovarian cancer. The effective rate of treatment is superior to that of traditional cisplatin + doxorubicin + cyclophosphamide, which is worthy of popularization and application.